

(19)



(11)

EP 2 873 678 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:

17.07.2024 Bulletin 2024/29

(45) Date of publication and mention
of the grant of the patent:

26.06.2024 Bulletin 2024/26

(21) Application number: **13816880.2**

(22) Date of filing: **11.07.2013**

(51) International Patent Classification (IPC):

A61K 47/64 ^(2017.01)	A61K 49/00 ^(2006.01)
A61K 49/04 ^(2006.01)	A61K 49/14 ^(2006.01)
C07K 7/08 ^(2006.01)	A61K 38/00 ^(2006.01)
A61K 31/711 ^(2006.01)	A61K 31/713 ^(2006.01)
A61P 1/16 ^(2006.01)	A61P 35/00 ^(2006.01)
A61P 35/02 ^(2006.01)	A61P 37/00 ^(2006.01)
A61P 37/02 ^(2006.01)	A61P 43/00 ^(2006.01)

(52) Cooperative Patent Classification (CPC):

A61K 31/711; A61K 31/713; A61K 47/64;
A61K 49/0047; A61K 49/0056; A61K 49/14;
A61P 1/16; A61P 35/00; A61P 35/02; A61P 37/00;
A61P 37/02; A61P 43/00; C07K 7/08; A61K 38/00

(86) International application number:

PCT/KR2013/006218

(87) International publication number:

WO 2014/010971 (16.01.2014 Gazette 2014/03)

(54) **CONJUGATE COMPRISING A CELL-PENETRATING PEPTIDE AND COMPOSITIONS
COMPRISING SAME**

KONJUGAT ENTHALTEND EIN ZELLPENETRIERENDES PEPTID UND ZUSAMMENSETZUNGEN
DAVON

CONJUGUÉ COMPRENANT UNE PEPTIDE DE PÉNÉTRATION CELLULAIRE, ET COMPOSITION
LE COMPRENANT

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **11.07.2012 KR 20120075444**

19.09.2012 KR 20120104173

28.09.2012 KR 20120109207

18.02.2013 KR 20130017046

19.04.2013 KR 20130043635

(43) Date of publication of application:

20.05.2015 Bulletin 2015/21

(73) Proprietor: **Gemvax & Kael Co., Ltd.**

Daejeon 34036 (KR)

(72) Inventor: **KIM, Sang Jae**

Seoul 135-947 (KR)

(74) Representative: **Inspicos P/S**

Agern Allé 24
2970 Hørsholm (DK)

(56) References cited:

EP-A1- 0 990 701	EP-A1- 2 615 105
WO-A1-00/02581	WO-A1-2012/033272
KR-A- 20070 083 218	KR-A- 20100 085 527
KR-A- 20110 130 943	KR-A- 20120 026 408
US-A1- 2011 318 380	US-A1- 2012 065 124
US-B1- 7 078 491	

- **LEE SEOUNG-AE ET AL: "Heat shock protein-mediated cell penetration and cytosolic delivery of macromolecules by a telomerase-derived peptide vaccine", BIOMATERIALS, vol. 34, no. 30, 1 July 2013 (2013-07-01), pages 7495 - 7505, XP028679351, ISSN: 0142-9612, DOI: 10.1016/J.BIOMATERIALS.2013.06.015**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).